StemCells Inc announced that interim six-month data from the first patient cohort in the Company’s Phase I/II clinical trial of its proprietary HuCNS-SC(R) product candidate (purified human neural stem cells) for chronic spinal cord injury continues to demonstrate a favorable safety profile, and shows considerable gains in sensory function in two of the three patients compared to pre-transplant baselines. The third patient remains stable.
The data was presented by Armin Curt, M.D., principal investigator for the clinical trial, at the 51st Annual Scientific Meeting of the International Spinal Cord Society in London, England. The trial represents the first
Ashok Chakravarti remembers the moment he went blind.
It was on February 18, 2002. He was at work, at a chemical plant, when a pipe carrying sodium hydroxide (caustic soda) started to leak.
“I was fixing the leak when the chemical splashed into my eyes,” he says. The accident damaged the outermost layer of his eyes, the cornea.
Chakravarti is among thousands of Indians who lose their sight in chemical accidents each year.
Today, some of those people can see again, thanks to scientists at the L.V. Prasad Eye Institute, in Hyderabad.
The institute is treating patients with stem cells – not the controversial
Doctors and scientists in Southampton have completed their first hip surgery with a 3D printed implant and bone stem cell graft.
The 3D printed hip, made from titanium, was designed using the patient’s CT scan and CAD CAM (computer aided design and computer aided manufacturing) technology, meaning it was designed to the patient’s exact specifications and measurements.
The implant will provide a new socket for the ball of the femur bone to enter. Behind the implant and between the pelvis, doctors have inserted a graft containing bone stem cells.
The graft acts as a filler for the loss of bone. The patient’s
Of all the alcoholic liver disease patients thronging the out-patient departments of the Post Graduate Institute of Medical Education and Research (PGIMER), nearly 50% are from Punjab.
What draws them to this institute is the stem cell treatment offered to the severe alcoholic hepatitis that acts as a boon.
PGI is the only tertiary hospital in the region which caters to this end-stage liver disease from Punjab, Himachal, Haryana and Chandigarh.
The stem cell treatment reports 78% success in cases of severe alcoholic hepatitis. A report on the same had been published in the prestigious American journal of gastroenterology this month. Moreover,
Image via Wikipedia
The first patient in the landmark Pilot Investigation of Stem Cells in Stroke (PISCES) trial has been treated with neural stem cells. The study is the first fully regulated clinical trial of neural stem cell therapy for stroke. Investigators will evaluate the safety of ReNeuron cells in disabled ischemic stroke patients.
“This is a first in man safety study,” lead investigator Keith Muir, MD, from the University of Glasgow‘s Institute of Neuroscience and Psychology in Scotland, explained to Medscape Medical News. “We are looking at neurological effects — clinical and imaging — only as secondary goals.”
The stem cells